Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
July 05, 2023 08:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement...
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
June 28, 2023 08:30 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group...
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
June 26, 2023 06:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today shared detailed results from its preclinical...
Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules
June 14, 2023 16:05 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced the...
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 13, 2023 08:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it...
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
June 08, 2023 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical...
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 15, 2023 16:05 ET
|
Biora Therapeutics, Inc.
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023 Preclinical testing for the BioJet™ platform...
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
May 08, 2023 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter...
Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer
May 01, 2023 09:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman,...
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference
April 20, 2023 16:46 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD...